BioTelemetry Enters Agreement to Provide Cardiac Monitoring for Apple’s Heart Study


MALVERN, Pa., Nov. 30, 2017 (GLOBE NEWSWIRE) -- BioTelemetry (NASDAQ:BEAT), the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today a partnership with Apple (NASDAQ:AAPL) to provide cardiac monitoring services in conjunction with the Apple Heart Study.  The study, which launched today, is expected to discover undiagnosed irregular heart rhythms, such as atrial fibrillation, using the Apple Watch and the dedicated “Apple Heart Study” App. 

Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “We are extremely excited to be participating in this potentially ground-breaking study.  Too often, the first indication of a cardiac arrhythmia is the occurrence of a life-threatening event.  The Apple initiative will potentially benefit countless individuals who are unaware that they may be at risk for serious health issues.”

About BioTelemetry
BioTelemetry, Inc. is the leading mobile and wireless medical technology company focused on delivery of health information to save and improve lives while reducing the cost of care.  The Company provides cardiac monitoring, mobile blood glucose monitoring, centralized medical imaging, and original equipment manufacturing that serve both the Healthcare and Clinical Research industries.  More information can be found at

BioTelemetry, Inc.
Heather C. Getz
Investor Relations


Back to news